Enacted by Congress in 2010, the Physician Payments Sunshine Act, commonly known as the Sunshine Act or Open Payments, is a part of the Patient Protection and Affordable Care Act. The directive of this legislation is to provide more transparency in the relationships between the healthcare industry and healthcare professionals. The Open Payment reporting system is being administered by the Centers for Medicare and Medicaid Services (CMS).
Johnson & Johnson has long supported the concept of transparency and the importance of a nationally standardized approach to reporting payments. Disclosing payments related to interactions with healthcare professionals fosters trust with patients, healthcare professionals and government officials. The breadth of our companies and our reach makes the results of our Open Payment reporting more robust and multi-faceted, encapsulating countless innovations, solutions and collaborations.
Please click on the appropriate link below for information on Open Payments:
- Janssen Pharmaceuticals, Inc. (therapeutic areas of focus are cardiovascular, type II diabetes and mental health)
- Janssen Biotech, Inc. (therapeutic areas of focus are oncology, immunology and nephrology)
- Janssen Therapeutics, Inc. (therapeutic areas of focus are hepatitis C and HIV)
- Janssen Research & Development